<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The primary objective of this study was to evaluate the safety of rituximab in <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (aPL)-positive patients with non-criteria manifestations of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>The secondary objectives were to evaluate the effect of rituximab on the aPL profile and to evaluate the efficacy of rituximab treatment for non-criteria manifestations of APS </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In this 12-month, phase II pilot study, adult aPL-positive patients with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:e sem="disease" ids="C0018824" disease_type="Disease or Syndrome" abbrv="">cardiac valve disease</z:e>, <z:hpo ids='HP_0200042'>skin ulcer</z:hpo>, aPL <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and/or <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e> received 2 doses of rituximab (1,000 mg) on days 1 and 15 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> profiles and clinical outcome measures, which were categorized as complete response, partial response, no response, or recurrence, were analyzed at preset time points </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Two of 19 patients experienced infusion reactions, resulting in early termination </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve serious adverse events and 49 nonserious adverse events were recorded </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients who had positive results of <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin, and anti-Î²(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibody tests at baseline had positive results at 24 weeks and 52 weeks </plain></SENT>
<SENT sid="7" pm="."><plain>The numbers of patients with a complete response, a partial response, no response, and recurrence for the clinical outcome measures at 24 weeks were as follows: for <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, 1, 1, 2, and 0, respectively; for <z:e sem="disease" ids="C0018824" disease_type="Disease or Syndrome" abbrv="">cardiac valve disease</z:e>, 0, 0, 3, and not analyzed, respectively; for <z:hpo ids='HP_0200042'>skin ulcer</z:hpo>, 3, 1, 0, and 1, respectively; for aPL <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, 0, 1, 0, and 0, respectively; and for <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunction</z:e>, 3, 1, 1, and not analyzed, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The results of this uncontrolled and nonrandomized pilot study suggest that the safety of rituximab in aPL-positive patients is consistent with the safety profile of rituximab </plain></SENT>
<SENT sid="9" pm="."><plain>Despite causing no substantial change in aPL profiles, rituximab may be effective in controlling some but not <z:hpo ids='HP_0000001'>all</z:hpo> non-criteria manifestations of APS </plain></SENT>
</text></document>